Interferon gamma-1b is under clinical development by Amgen and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase ...

Interferon gamma-1b is under clinical development by Amgen and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Relapsed Acute Myeloid Leukemia ...

Objective Standard assessment of interferon (IFN) system activity in systemic rheumatic diseases depends on the availability of RNA samples. In this study, we describe and evaluate alternative methods ...

Learn about Arbutus's promising Hepatitis B treatments, strong financial position, and projections for the global market.

imperial.ac.uk Background Interferon gamma release assays (IGRAs ... Furthermore, the role of IGRAs in the diagnostic work-up of active TB is unclear, and there is little evidence supporting use of ...

Investigational once-weekly retatrutide yielded the greatest weight loss of all GLP-1 receptor agonists, up to 22.1% after 48 ...

If you’re looking to save money on gas but don’t want a fully electric vehicle, a hybrid might be the right choice for you. Hybrids don’t need to be plugged in and they can be filled up at ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated ...

Both dose levels of modakafusp alfa “resulted in good response rates with similar safety profiles,” according to researchers.

Since precipitation as it falls generally moves with the wind, you can determine the wind velocity with Doppler technology. Although already invented, radar was further developed during World War II, ...

Challenge trials help researchers study immune responses. Skeptics still doubt the approach is worth the risks ...